Project Grant HT94252310130
Award Date
7/1/23
Completion Date
6/30/26
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Detroit, MI 48202, USA
Similar Awards
The Defense Health Agency awarded Wayne State University a $616,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to investigate the molecular mechanisms and therapeutic potential of the RNA methyltransferase FTSJ3 in regulating ribosome biogenesis in liver cancer. The project will be conducted over a 2-year period from September 30, 2023 to September 29, 2025. As a premier public research university, Wayne State University has a track record of...
The U.S. Department of Defense's Defense Health Agency awarded a $693,000 Project Grant to Wayne State University in Detroit, Michigan under the Military Medical Research and Development program (CFDA 12.420). The grant supports the university's "EPIGENETIC THERAPEUTIC TARGETING OF ENHANCER HUBS FOR BREAST CANCER" research project, which aims to develop new treatments for breast cancer. The 3-year award, running from December 15, 2023 to December 14, 2026, will fund basic,...
This $924,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Wayne State University to target dual-specificity phosphatase 1 in platinum resistance in ovarian cancer. The award, which runs from July 1, 2024 to June 30, 2028, will enable Wayne State to conduct innovative scientific studies to improve treatment options and outcomes for this challenging form of cancer, which disproportionately impacts...
Wayne State University was awarded a $538,792 project grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting TINAGL1 to Enhance Immunotherapy Response in Lung Cancer." The three-year award beginning May 1, 2023 will support the university's efforts to investigate medical solutions for battlefield injuries and transform military and public health care through innovative biomedical research....
The Washington State University will receive $1,377,000 from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on the novel role and therapeutic targeting of LMO4 in lethal prostate cancer from July 1, 2023 to June 30, 2026. Through this three-year Project Grant, WSU researchers will investigate medical solutions for the battlefield by exploring the oncogenic functions of LMO4 and developing targeted therapies to...
This $385,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports Wayne State University's research to develop therapeutic approaches targeting spiral ganglion-cochlear nucleus synaptopathy. The two-year award, running from September 1, 2023 to August 31, 2025, aims to transform health care for Service Members and the American public through innovative and impactful biomedical research. As a prominent public...
The University of Michigan was awarded a $900,640 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2021 through August 2024 to target chromatin remodeling complexes in order to inhibit oncogenic androgen receptor activity in prostate cancer. Through basic, applied, and advanced biomedical research supported by this program, the University aims to...
The University of Michigan received a $925,834 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research into CDK12 as a context-specific tumorigenesis regulator and novel therapeutic target in castration-resistant prostate cancer. The research will be performed in Ann Arbor, Michigan over a three-year period from September 2021 through August 2024. Through the support of basic,...
This $785,833 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. Awarded to the University of Wisconsin System, the research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to disease prevention, diagnosis,...
The University of Washington was awarded a $1,312,384 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from August 1, 2022 to July 31, 2025 to target FZD6 sensitization of advanced prostate cancer to genotoxic stress. Through this funding, researchers at the University of Washington aim to investigate medical solutions for prostate cancer by exploring how targeting...